Table 3.

Number of ARQ 197 months administered in each dosing cohort

Pt #Dose, mg twice a dayTumor typeBest responseTime on study, wk
46120Adenoid cysticSD63
640–70AngiomyolipomaSD35
36180Bladder carcinomaSD22
70360Bladder transitional cell carcinomaSD14
53120Endometrial adenoca (poorly differentiated)SD12
30120LiposarcomaSD41
43150MelanomaSD12
110–50NeuroendocrinePR32
50120Neuroendocrine (high-grade, unknown primary)SD20
1470NSCLCSD17
530–50NSCLC (adenocarcinoma)SD20
740–120Pancreatic carcinomaSD102
52120Papillary adenoca of unknown primarySD39
26120Papillary thyroid carcinomaSD20
27120–150Papillary thyroid carcinomaSD119
38180Papillary thyroid carcinomaSD66
840–70Prostate carcinomaPR29
44150Rectal carcinomaSD21
2090–120Renal Cell carcinomaSD36
28120–150Renal Cell carcinomaSD66
77360Renal Cell carcinomaSD12
65120Renal Clear Cell carcinomaSD28
73360Renal Clear Cell carcinomaSD30
34150Renal Clear Cell carcinomaSD21
32150SarcomaSD47
45150Small cell undifferentiated carcinomaSD21
2290–120Testicular carcinomaPR66